Actively Recruiting
Prognosis of Patients With Mixed Cardiogenic-Vasoplegic Shock A French Multicenter Cohort
Led by Centre Hospitalier Universitaire, Amiens · Updated on 2026-01-21
2500
Participants Needed
1
Research Sites
21 weeks
Total Duration
On this page
Sponsors
C
Centre Hospitalier Universitaire, Amiens
Lead Sponsor
C
Centre Hospitalier Universitaire Dijon
Collaborating Sponsor
AI-Summary
What this Trial Is About
Mixed cardiogenic-vasoplegic shock (M-CS) is a serious condition combining heart dysfunction and abnormal blood vessel dilation. This observational study aims to better understand the outcomes and factors linked to this condition by examining data collected during routine care. Patients included have cardiogenic shock, with or without vasoplegia, defined by low heart output and sometimes low blood vessel resistance even with proper fluid levels and the need for vasopressors. The study collects information from patients admitted to intensive care units in three French hospitals. It includes two groups: those with mixed cardiogenic-vasoplegic shock requiring norepinephrine at certain doses to maintain blood pressure, and those with cardiogenic shock without vasoplegia. No experimental treatments are given as this is a non-interventional registry. Participants’ data, including clinical details, treatments, and outcomes, will be analyzed for up to 90 days. Key measures include death rates, organ failure, blood pressure changes, vasopressor needs, and length of ICU and hospital stay. The study will provide valuable insights into this complex condition by reviewing routine health records over time.
CONDITIONS
Brief Title
Prognosis of Patients With Mixed Cardiogenic-Vasoplegic Shock
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patient (>18 years old)
- Admitted to an intensive care unit for cardiogenic shock, at least SCAI stage C
- No opposition to data use
You will not qualify if you...
- Missing key data, particularly regarding vasopressor doses and outcomes
- Pregnant women
- Non-eligible shock etiologies, including anaphylactic shock, isolated hemorrhagic shock, severe burns or major trauma, severe acute pancreatitis, fulminant hepatic failure, neurogenic shock
- Adult under legal protection (guardianship, curatorship, or judicial protection)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 90 days
Participants hospitalized in intensive care units for cardiogenic shock are observed to collect clinical characteristics, management trajectories, and outcomes.
Daily assessments during ICU stay and additional evaluations up to 90 days
Trial Site Locations
Total: 1 location
1
CHU Amiens Picardie
Amiens, Somme, France, 80000
Actively Recruiting
Research Team
C
Christophe Beyls, MD, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here